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a r t i c l e s
Treatment of primary immunodeficiencies with gene-modified autologous stem cells may offer considerable benefits over allogeneic cell transplantation, particularly when human leukocyte antigen (HLA)-matched donors are not available. Phase 1/2 clinical trials aimed at the correction of X-linked severe combined immunodeficiency (SCID-X1) and adenosine deaminase−deficient SCID (ADA-SCID) using gammaretroviral vectors have successfully demonstrated reconstitution of immunity and correction of metabolic toxicities [1] [2] [3] [4] [5] . However, the occurrence of leukemias as a consequence of retroviral integration observed in five SCID-X1 cases has illustrated the risk associated with inadvertent proto-oncogene activation [6] [7] [8] [9] .
We applied gene therapy to treat X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency that is characterized by recurrent severe bacterial and fungal infections due to a functional defect in the microbe-killing activity of phagocytic neutrophils [10] [11] [12] [13] . Two young adults with X-CGD were treated with autologous gene-modified cells in combination with nonmyeloablative conditioning. Successful engraftment of gene-transduced cells resulted in the eradication of pre-existing life-threatening bacterial and fungal infections. However, insertional activation of MDS1−EVI1 and the genes encoding PR domain−containing protein 16 (PRDM16) and SET-binding protein 1 (SETBP1) triggered a threefold to fivefold increase in the number of gene-transduced cells in the peripheral blood of both subjects 14 , leading to oligoclonal hematopoiesis, monosomy 7 and the development of a myelodysplastic syndrome (MDS).
RESULTS

Clinical findings
After gene therapy, subject 1 remained well and clinically stable for almost 18 months, during which time we discontinued antimicrobial prophylaxis. However, after a routine checkup at month 15, we noted declining white blood cell counts (platelets, 45,000 µl −1 ; neutrophils, 1,600 µl −1 ; lymphocytes, 1,200 µl −1 ) (Fig. 1a) . Bone marrow biopsies taken at months 15 and 18 showed declining cellularity with left-shifted hematopoiesis and an increased number of macrophages, but no signs of myelodysplasia or malignancy (Supplementary Fig. 1a ).
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease a r t i c l e s
The subject received daily granulocyte colonystimulating factor (G-CSF) support (5 µg per kg body weight per day) from months 18 to 20 and months 24 to 26, as well as multiple red blood and platelet transfusions. Following a dental abscess and a febrile episode requiring antibiotic and antimycotic treatment, subject 1 was noted to have extensive splenomegaly and underwent splenectomy at month 25 to avoid spontaneous rupture. Histopathological examination of the spleen revealed extramedullary hematopoiesis and siderosis in the red pulp, without signs of dysplasia, and increased infiltration with activated macrophages showing hemophagocytosis. After a transient improvement, at month 26, he developed a pseudomembranous colitis with perforation and underwent colectomy. He died 27 months after gene therapy of multiorgan failure owing to septic shock. The postmortem pathology is described in detail in the Supplementary Notes. Retrospectively, the occurrence of cytopenia and the presence of uniformly vacuolated monocytic cells in the peripheral blood at month 27, together with the finding of monosomy 7 (see below), indicates that subject 1 developed MDS as consequence of gene therapy, probably with transition to acute myeloid leukemia (AML) with organ infiltration at the time of death.
Routine clinical and laboratory examinations of subject 2 up to 22 months after gene therapy documented a stable clinical status, with no severe infections and no alterations in peripheral blood counts or bone marrow morphology. However, 28 months after gene therapy, he developed mild pancytopenia (macrocytic, hyperchromic anemia; hemoglobin, 11.8 g dl −1 ; platelets, 125,000 µl −1 ; decreasing neutrophil counts) (Fig. 1b) . Serial routine bone marrow biopsies revealed normal cellularity and cytogenetics until month 33, when we first noted mild hypocellularity (approximately 70% of normal cell concentrations), without dysplasia or blasts (Supplementary Fig. 1d) . By month 43, a bone marrow aspirate revealed severe hypocellularity, increased erythropoiesis and multilineage dysplasia with less than 5% blast cells (Supplementary Fig. 1e,f) , consistent with refractory cytopenia with multilineage dysplasia (RCMD) according to the World Health Organization (WHO) criteria. At month 45, subject 2 underwent allogeneic stem cell transplantation from a fully matched, unrelated donor. For details, see the Supplementary Notes and Supplementary Figure 2 .
Gene marking and NADPH oxidase activity in transduced cells
As a result of EVI1-and MDS1−EVI1-triggered clonal expansion 14 , the percentages of gene-transduced peripheral blood neutrophils remained between 50% and 65% until month 26 and month 36 for subjects 1 and 2, respectively (Fig. 1c,d) . Thereafter, we observed a decrease in gene marking in peripheral blood granulocytes of subject 2, with 30% gene-transduced cells present at 40 months after transplantation. Gene marking in bone marrow mononuclear cells (BM MNCs) of subject 2 remained constant, between 40% and 50%, whereas gene marking in lymphocytes remained stable at 10%-15% in B cells and less than 3% in T cells ( Supplementary Fig. 3a,b) . Despite high numbers of gene-marked cells, the number of oxidase-positive granulocytes progressively decreased from month 9 and month 15 for subjects 1 and 2, respectively, and correlated with a concomitant decrease in the amount of GP91-PHOX transcript (encoding gp91 phox ) in peripheral blood granulocytes (Fig. 1c,d) . We used bisulfite sequencing to analyze vector methylation in samples from subjects 1 and 2 and found that increased methylation at a CpG island within the promoter region of the viral long terminal repeat (LTR) correlated with the lack of GP91-PHOX expression and superoxide production observed in the peripheral blood cells of both subjects ( Fig. 2a and Supplementary Fig. 4) . Notably, we detected no methylation at CpG dinucleotides within the enhancer region of the LTR, suggesting a selective pressure for this epigenetic fingerprint.
Clonal distribution of gene-marked cells
The highly polyclonal population of transduced cells observed shortly after transplantation 14 progressively became clonally restricted and dominated by clones containing retroviral integrations in the MDS1−EVI1 gene locus (Fig. 2b) . In peripheral blood samples of subject 1, we detected a single dominant clone containing the integration 75916A08, initially at month 4 at a frequency of 3% within total gene-marked hematopoiesis. Its contribution increased steadily, reaching 35% at month 11 (Fig. 2c) . Methylation analysis of this clone revealed a nonmethylated LTR ( Supplementary  Fig. 5 ), linking clone 75916A08 to the restored superoxide production observed in granulocytes from this subject during the first 10-18 months after gene therapy. From month 24 onward the clonal repertoire was dominated by clone 76776G11, which contained a fully methylated promoter region and accounted for >90% of the genemarked hematopoiesis at month 26 ( Fig. 2c and Supplementary Fig. 5 ). As both dominant clones contained integrations in the MDS1 gene locus, increased expression of EVI1 or secondary mutations may have contributed to the dominance of clone 76776G11 over other clones with similar integrations.
We observed a similar shift toward oligoclonality in peripheral blood cells of subject 2. Two MDS1−EVI1 clones, 87429F02 and 87429A02, dominated gene-marked hematopoiesis between Gene-modified granulocytes Oxidase-positive cells GP91-PHOX mRNA levels a r t i c l e s months 28 and 33 ( Fig. 2b,c ), but at later time points, we detected only clone 87429F02. This clone showed extensive methylation at the promoter region of the viral LTR, which was already detectable 5 months after transplantation ( Supplementary Fig. 5 ).
In both subjects 1 and 2, we detected MDS1−EVI1 and EVI1 transcripts in peripheral blood mononuclear cells (PBMCs) and granulocytes after gene therapy, but they were absent from samples taken before gene therapy, clearly indicating that transcriptional activation of the MDS1−EVI1 gene locus was retrovirus dependent (Fig. 2d) . In both subjects the MDS1−EVI1 transcript contained the second exon of the MDS1 gene spliced to the second exon of the EVI1 gene, generating a fusion transcript identical to that found in leukemias with 3q26 rearrangements 15 , and the EVI1 transcripts contained exon 1b. In subject 2, we also detected EVI1 transcripts and MDS1−EVI1 fusion transcripts in bone marrow−derived colonies containing either the 87429F02 or the 87429A02 integration (Fig. 2d, below) . EVI1 expression increased with time in both subjects, and EVI1 transcript levels in the dominant clones 76776G11 (subject 1) and 87429F02 (subject 2) were comparable to those found in a human cell line with EVI1 rearrangement 16 . In contrast, MDS1−EVI1 expression contributed less than 1% to the total level of EVI1 transcript in the dominant clones (Supplementary Fig. 6 ).
Clonal dominance is associated with monosomy 7
Using a retrospective chromosome copy number variation (CNV) analysis based on single-nucleotide polymorphism (SNP) arrays, we identified a series of chromosomal regions that were amplified in both subjects, mainly at months 26 and 27 for subject 1 and months 35 and 38 for subject 2 (Supplementary Table 1) . From month 21 onward, we identified a loss of one chromosome 7 in the PBMCs of subject 1 (Fig. 3a) . The frequency of cells containing a single chromosome 7 increased up to 80% at month 27, a time point at which clone 76776G11 dominated gene-marked hematopoiesis (>75% contribution to gene marking). Results obtained by interphase fluorescence in situ e Nontransduced M33 f a r t i c l e s hybridization (I-FISH) were consistent with these findings. At month 27 we detected monosomy 7 in almost all PBMCs, whereas at month 13 we found no chromosomal abnormalities BM MNCs (Fig. 3b,c) .
In subject 2, there were no changes in chromosomal copy number in BM MNCs for the first 33 months, as analyzed by I-FISH. However, at month 33 we detected monosomy 7 in BM MNCs at a frequency of about 25%, as shown by I-FISH and metaphase chromosome analysis ( Fig. 3d and Supplementary Fig. 7b) . Thereafter, the percentage of monosomy 7 cells in subject 2 increased to 50% at month 45. Analysis of single hematopoietic colonies derived from bone marrow samples from subject 2 showed that monosomy 7 was linked to clone 87429F02 (Fig. 3e) and was not detectable in nontransduced cells (Fig. 3f) Fig. 7c ), suggesting that monosomy 7 originated in at least one, probably myeloid, progenitor cell in which the MDS1−EVI1 gene locus was transcriptionally activated by retroviral insertion.
. Notably, metaphase (M)-FISH analysis of interleukin-2 (IL-2)-expanded T cells of subject 2 from months 31 and 33 did not show any chromosomal rearrangements (Supplementary
The occurrence of monosomy 7 together with the clinical findings for both subjects was consistent with a diagnosis of MDS. In line with this observation, a genome-wide methylation analysis of 807 cancer-related genes revealed a DNA methylation pattern characteristic of patients with MDS and AML 17, 18 (Supplementary Tables 2 and 3) . Among others, the gene encoding p15 INK4B , CDKN2B, whose frequent methylation in individuals with MDS or AML is associated with deletions of genes on chromosome 7q 19 , was hypermethylated in peripheral blood samples from both subjects. We found that CDKN2B methylation correlated well with the appearance of monosomy 7−containing cells in the peripheral blood of subjects 1 and 2 ( Supplementary Fig. 8 ).
Increased genomic instability in MDS1−EVI1-expressing cells
Phosphorylation of histone H2AX is one of the earliest events detectable after induction of DNA double-strand breaks (DSBs) [20] [21] [22] . We detected an 8-fold to 12-fold increase in the number of foci per cell with phosphorylated H2AX (γ-H2AX) in PBMCs of subject 1 at month 27 and BM MNCs of subject 2 at month 43. Whereas before gene therapy almost no γ-H2AX foci were detectable in peripheral blood samples from subject 1, at month 4 we detected DSBs in ~14% of the cells, with a mean value of 0.15 foci per cell (Fig. 4) . At this time point, the total MDS1−EVI1 clonal contribution to genemodified cells was 13.2%. At 27 months after gene therapy, when gene-marked hematopoiesis was dominated by the monosomy 7 clone 76776G11 (Fig. 2c) , the concentration of DSBs in PBMCs increased to a mean value of 0.6 foci per cell, with 34% of the cells having one or more γ-H2AX foci per cell (Fig. 4a,c) . In subject 2, the percentage (Fig. 4b,d) .
As genomic instability has been linked to centrosomal aberrations [23] [24] [25] , we transduced human diploid BJ fibroblasts with EVI1 expression constructs to determine whether overexpression of EVI1 induces centrosomal amplification. Compared to BJ fibroblasts transduced with a vector expressing enhanced green fluorescent protein (EGFP), cells overexpressing EVI1 showed an increased frequency of centrosomal aberrations, as determined by increased numbers of centrosomes in almost 16% of the EVI1-expressing cells (Fig. 5) . Similarly, overexpression of MDS1−EVI1 in BJ fibroblasts led to a twofold to threefold increase in centrosome numbers, suggesting equal functions for EVI1 and MDS1−EVI1 in this regard (Supplementary Fig. 9) .
In contrast, the number of centrosomes in fibroblasts stably expressing gp91 phox or its catalytic inactive form, gp91 phox (P415H) 26 did not differ from that found in nontransduced cells or in cells expressing EGFP (Fig. 5) . We conclude that the insertional activation of EVI1 was the dominant factor leading to centrosomal aberrations and genomic instability in our patients that resulted in the development of MDS with monosomy 7.
DISCUSSION
Gene therapy provided clear clinical benefit in this clinical trial 14 , with both subjects initially recovering from life-threatening bacterial and fungal infections. However, long-term benefit was compromised by vector inactivation, resulting in a lack of microbicidal activity in gene-transduced phagocytic cells. Although vector inactivation has been reported in cell lines, embryonic and mouse hematopoietic stem cells 27, 28 , methylation of the vector promoter has not been reported in clinical studies so far. In other immunodeficiencies, powerful positive-selection pressures may have obscured this phenomenon, as nonexpressing progenitors would not support further survival and differentiation. However, a partial methylation of the spleen focusforming virus (SFFV) LTR has been observed in a clinical trial of gene therapy for ADA-SCID (ref. 4 and A. J. Thrasher, personal communication), suggesting that the SFFV LTR is prone to methylation in human hematopoietic cells.
In X-CGD, expression of gp91 phox is not necessary for cell survival, and gp91 phox is not known to confer a proliferative advantage to myeloid progenitors. A direct role for the therapeutic gp91 phox protein in the clonal proliferation observed in our study is unlikely because gp91 phox expression decreased with time in both subjects owing to silencing of the LTR promoter. Although initially there was a good correlation between clonal expansion and GP91-PHOX expression in the peripheral blood of subject 1, and to a lesser extent also in subject 2, within the first months after gene therapy, we eventually detected methylation-dependent silencing of GP91-PHOX expression in most, but not all, of the clones analyzed (Supplementary Fig. 5) . Methylation of the viral promoter seems to correlate with global methylation at the site of integration 29 , suggesting that the epigenetic events occurring at the vector LTR in our trial reflected epigenetic marks at the site of integration. The lack of methylation at the enhancer region of the LTR may reflect a selective pressure for a vector-dependent transactivation of EVI1 and MDS1−EVI1, as clonal expansion was linked to the continuous expression of these proto-oncogenes.
Gene-transduced hematopoiesis in both subjects was dominated by clones containing retroviral insertions within the MDS1−EVI1 gene locus. This locus represents one of the most common targets of retrovirus integration observed in vitro and in vivo 30 . In animal models, retrovirus-mediated transcriptional activation of Evi1 has been associated with extensive proliferation and self-renewal of hematopoietic progenitor cells, increased engraftment potential and clonal dominance 31, 32 . In mouse hematopoiesis, the insertional activation of Evi1 can also lead to leukemia of myeloid or lymphoid origin 33, 34 , whereas ectopic expression of Evi1 in bone marrow cells induces a fatal MDS after an initial period of myeloproliferation 35, 36 . However, chromosomal aberrations as a consequence of Evi1 overexpression have not been reported in any in vitro or in vivo study to date 30, 34 .
In humans, transcriptional activation of EVI1 is often associated with MDS and AML [37] [38] [39] . In MDS, rearrangements involving 3q26 (EVI1) can be found either as the only cytogenetic aberration, or associated with additional chromosomal abnormalities, most often monosomy 7 (refs. 40-43) . Neither the exact link between 3q26 rearrangements and loss of one chromosome 7, nor the sequential order of events leading to MDS, has been clarified. Gene marking of individual hematopoietic clones by retroviral insertion provides a basis to dissect the order and mechanism of the molecular and cellular events leading to malignancy. In the evolution of leukemia in the gene therapy studies for SCID-X1, oncogene activation through insertional mutagenesis was associated with the accumulation of additional genetic lesions 8, 9 . In our study, we observed profound clonal expansions driven by the insertional activation of EVI1, MDS1−EVI1 and PRDM16, a homolog of MDS1−EVI1, in multiple clones of both subjects 5 months after gene therapy. We detected no abnormalities in blood counts, bone marrow morphology or karyotype during this period, indicating that this insertional event was probably the driving event for progression toward clonal dominance.
In addition to the role of EVI1 and MDS1−EVI1 in development, transcriptional regulation, self-renewal and cell cycle progression [44] [45] [46] [47] , EVI1 has been shown to interact with proteins involved in the chromatin-remodeling process, including BRG1, SUV39H1, G9a and MBD3B, and may thereby influence proper centrosome replication, chromatin assembly and genomic stability [48] [49] [50] [51] [52] . During mitosis, centrosomes function as spindle poles, directing the formation of bipolar spindles, a process essential for accurate chromosome segregation 53 . Centrosome amplification may lead to chromosomal instability and has been frequently observed in both solid tumors and hematological malignancies, including myelodysplastic syndromes and AML 23, 24 . In line with these observations, our analysis indicates profound genomic instability in EVI1-and MDS1−EVI1-expressing clones. At month 27, PBMCs of subject 1 showed a 12-fold increase in the number of γ-H2AX foci per cell, compared to control cells. Similarly, we observed a 1.9-fold to 8.1-fold increase in the number of foci per cell in samples taken from subject 2.
The increase in DNA DSBs preceded the onset of myelodysplasia and, together with increasing clonal dominance, was highly predictive of abnormal hematopoiesis. Genomic instability was linked to the aberrant expression of EVI1 and MDS1−EVI1, as overexpression of either gene in human diploid fibroblasts caused a twofold to threefold increase in abnormal centrosome numbers in transduced cells. We speculate that this effect could be mediated by the binding of EVI1 to G9a, a H3K9-specific histone methyltransferase. EVI1−G9a complexes have reduced methytransferase activity, and downregulation of G9a activity has been linked to centrosome disruption and chromosome instability in cancer cells 50, 52 .
Although we observed increased EVI1 and MDS1−EVI1 expression in the bulk population of expanded hematopoietic clones, two clones, one in each subject, dominated gene-marked hematopoiesis at later time points. Both clones, 76776G11 (subject 1) and 87429F02 (subject 2), a r t i c l e s expressed EVI1 at levels similar to those found in leukemic cells containing EVI1 rearrangements, and both lost one copy of chromosome 7. In contrast, MDS1−EVI1 transcript levels were at least 100-fold lower than those of EVI1. It is therefore tempting to speculate that deletion of one chromosome 7 occurred in clones expressing EVI1 at high levels. This hypothesis is supported by the observations made for subject 2. At month 11, the total contribution of clones containing MDS1−EVI1 integrations to gene-marked hematopoiesis in peripheral blood was 87%, but total EVI1 expression was low. At month 37, the contribution of the monosomy 7−containing clone to gene marking was almost 50%, whereas EVI1 expression levels were equal to or higher than that found in a leukemic cell line with inv(3).
Alternatively, high EVI1 expression levels may have been triggered by haploinsufficiency of EVI1 transcriptional regulators on chromosome 7. In this context, it is noteworthy that the myeloid/lymphoid or mixed-lineage leukemia 5 gene (MLL5), a trithorax homolog with a crucial role in adult hematopoiesis and a postulated role in chromatin remodeling and in the control of cellular growth, was recently mapped to 7q22, a region that is frequently deleted in AML [54] [55] [56] [57] .
A contribution of gp91 phox expression to aberrant hematopoiesis is unlikely, as was observed promoter methylation in the monosomy 7−containing clones as early as 1 month after gene therapy in the dominant clone 76776G11 and 5 months after transplantation in the dominant clone 87429F02, much earlier than the onset of dysplasia and monosomy 7. Also, forced expression of gp91 phox in human diploid fibroblasts did not induce alterations in centrosome numbers above those found in mock-transduced cells or in cells expressing a catalytically inactive form of gp91 phox . In agreement with this, we have not detected increased concentrations of reactive oxygen species in gp91 phox -expressing cells. Similarly, we believe that the administration of G-CSF did not influence disease progression, as disease development and outcome was identical in both subjects, but only subject 1 received G-CSF (further details in the Supplementary Notes).
Despite the severe adverse effects observed in our trial, the initial eradication of preexisting life-threatening bacterial and fungal infections and other clinical benefits experienced by both subjects for more than 2 years after reinfusion of their autologous gene-modified cells are clear evidence that gene therapy can be an effective strategy for the long-term correction of CGD. Improved vector designs should enable the safe and effective application of gene therapy for the long-term correction of CGD and other inherited disorders, as demonstrated recently 58 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
